EMG
ARLZ

Ellington Management Group’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Ellington Management Group’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-25,500
Closed -$124K – 973
2016
Q3 		$124K Buy
+25,500
New +$116K 0.03% 599

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
TLCM
Tiger Legatus Capital Management New York $62.4M AUM 24.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ellington Management Group's ARLZ Position: Q4 2016 in Review

Ellington Management Group sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q4 2016, closing a stake of 25,500 shares — an estimated $124K sold.

Ellington Management Group first reported a position in ARLZ in Q3 2016 and held it in 1 quarter. The position peaked at $124K in Q3 2016. 83 funds tracked by Wall St. Rank hold ARLZ as of Q4 2016.

  • Ellington Management Group reported no remaining Aralez Pharmaceuticals Inc. position as of Q4 2016 after selling out during the quarter.
  • Ellington Management Group sold 25,500 Aralez Pharmaceuticals Inc. shares in Q4 2016, an estimated $124K.
  • Ellington Management Group first reported a position in Aralez Pharmaceuticals Inc. in Q3 2016 and held it in 1 quarter.
  • Ellington Management Group's Aralez Pharmaceuticals Inc. position peaked at $124K in Q3 2016.
  • 83 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q4 2016.

Based on Ellington Management Group's 13F filing for Q4 2016, filed 14 Feb 2017.